
- December 2019
- Volume 85
- Issue 12
Mental Health Watch: Cognitive Impairment Is Linked to Presence of Persistent HIV in CNS
Many individuals with HIV who are receiving antiretroviral therapy have viral genetic material in the cells of their cerebrospinal fluid, making them more likely to experience memory and concentration problems, according to the results of a new study.
Many individuals with HIV who are receiving antiretroviral therapy (ART) have viral genetic material in the cells of their cerebrospinal fluid (CSF), making them more likely to experience memory and concentration problems, according to the results of a new study published in the Journal of Clinical Investigation.
Investigators from the University of North Carolina, the University of Pittsburgh, and Yale University studied participants in the AIDS Clinical Trials Group HIV Reservoirs Cohort Study. They studied a primarily male group, aged 45 to 56 years, of long-term HIV survivors with infections controlled with ART for an average of 9 years. The investigators analyzed each participant’s CSF for HIV DNA and compared these data with each participant’s results from standard neurocognitive evaluations.
The authors evaluated 69 individuals on long-term ART and found that nearly half had persistent HIV in cells in their CSF, indicating the presence of latent virus, even though standard HIV RNA viral load tests of the cell-free CSF fluid were positive in only 4% of the participants. Investigators also found that 30% of this subset experienced neurocognitive difficulties compared with 11% of individuals whose CSF did not contain viral DNA.
These findings suggest that the presence of persistent HIV-infected cells in the CNS, despite long-term ART, may play a role in neurocognitive impairment.
REFERENCE
Persistent HIV in central nervous system linked to cognitive impairment [news release]. Bethesda, MD: National Institutes of Health; July 16, 2019. nih.gov/news-events/news-releases/persistent-hiv-central-nervous-system-linked-cognitive-impairment. Accessed September 24, 2019.
Articles in this issue
almost 6 years ago
Individualizing COPD Treatment to Improve Adherence and Overall Outcomesalmost 6 years ago
2019 Was a Year for Advancements in Infectious Diseasealmost 6 years ago
OTC Case Studies: Feveralmost 6 years ago
Generic Products (December 2019)almost 6 years ago
Can You Read these Rxs? (December 2019)almost 6 years ago
Pet Peeves (December 2019)almost 6 years ago
Case Studies (December 2019)almost 6 years ago
Aimovig Can Cut the Number of Migraine Daysalmost 6 years ago
Get Up to Speed on UTIsNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.